SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction
SGLT2 inhibitors (dapagliflozin 10 mg daily or empagliflozin 10-25 mg daily) should be initiated in all patients with HFrEF (LVEF ≤40%) regardless of diabetes status, as they significantly reduce cardiovascular death and heart failure hospitalizations while improving symptoms and quality of life. 1, 2
Core Benefits: Mortality and Morbidity Reduction
The landmark DAPA-HF and EMPEROR-Reduced trials established SGLT2 inhibitors as cornerstone therapy for HFrEF, demonstrating:
- 25-26% reduction in the composite of cardiovascular death or heart failure hospitalization 1, 3
- 30% reduction in heart failure hospitalizations specifically 3
- Cardiovascular mortality reduction of 23% 4
- Benefits consistent regardless of diabetes status 1, 2
These effects were achieved on top of maximally tolerated guideline-directed medical therapy including ACE inhibitors/ARBs/ARNI, beta-blockers, and mineralocorticoid receptor antagonists 3, 2.
Quality of Life and Functional Improvements
Beyond hard endpoints, SGLT2 inhibitors provide tangible symptomatic benefits:
- Improved Kansas City Cardiomyopathy Questionnaire scores 5
- Enhanced left ventricular ejection fraction and global longitudinal strain 6
- Improved right ventricular function 6
- Reduced blood pressure by approximately 2 mmHg 3
These improvements occur within 3-6 months of therapy initiation and persist long-term 6.
Renal Protection
SGLT2 inhibitors provide crucial kidney benefits in HFrEF patients:
- Slower eGFR decline (−0.55 vs −2.28 mL/min/1.73 m² per year with empagliflozin) 3
- 50% reduction in composite renal outcomes (chronic dialysis, transplantation, or sustained eGFR reduction) 7
- Benefits maintained even with baseline eGFR as low as 20-30 mL/min/1.73 m² 3, 2
Practical Implementation
Dosing:
- Dapagliflozin: 10 mg daily (starting and target dose) 1
- Empagliflozin: 10 mg daily (starting), target 10-25 mg daily 1
Timing of Initiation: Start SGLT2 inhibitors early in the disease course—do not wait for optimization of other GDMT 2. Recent evidence supports in-hospital initiation during heart failure hospitalization or within 6 weeks post-discharge, which is associated with:
- 25% reduction in 1-year all-cause mortality 8
- 14% reduction in all-cause hospitalizations 8
- Improved medication adherence and implementation 9
However, only 21.3% of eligible patients currently receive SGLT2 inhibitors within this optimal window 8, representing a significant treatment gap.
Safety Profile and Monitoring
Common but manageable adverse effects:
- Genital mycotic infections (10-15% in women, higher in uncircumcised men) 2
- Typically managed with antifungal therapy without discontinuation
- Temporary eGFR reduction up to 15% in first 1-3 months 2
- Generally resolves; does not require discontinuation unless acute kidney injury develops
Contraindications:
Critical caveat: Hold SGLT2 inhibitors during acute illness, dehydration, or "sick days" to prevent volume depletion and acute kidney injury 2.
Mechanism of Benefit
While the precise mechanisms remain incompletely understood, SGLT2 inhibitors exert multiple beneficial effects:
- Osmotic diuresis and natriuresis reducing preload 1, 11
- Restored tubuloglomerular feedback 11
- Anti-inflammatory and antifibrotic effects 1
- Reduced oxidative stress and improved endothelial function 1
- Improved myocardial energetics 12
- Reverse cardiac remodeling 1
These pleiotropic effects collectively contribute to the observed clinical benefits beyond simple glucose lowering 1, 12.
Guideline Recommendations
The 2025 Canadian Cardiovascular Society/Canadian Heart Failure Society guidelines and 2022 AHA/ACC/HFSA guidelines provide Strong Recommendations with High-Quality Evidence for SGLT2 inhibitor use in HFrEF 1, 2, 13. This represents the highest level of recommendation, placing SGLT2 inhibitors alongside ARNI, beta-blockers, and MRAs as foundational HFrEF therapy.
The evidence is unequivocal: SGLT2 inhibitors reduce death, prevent hospitalizations, and improve quality of life in HFrEF patients. They should be initiated early, maintained chronically, and considered essential therapy for all eligible patients with LVEF ≤40%.